Recent Updates
Recently added Catalysts
PEPG Negative Sentiment

PEPGEN ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against PepGen, Inc. and Encourages Investors to Contact the Firm

Key Takeaway: Bragar Eagel & Squire, P.C. has announced the filing of a class action lawsuit against PepGen, Inc. in the U.S. District Court for the Eastern District of New York. The lawsuit is on behalf of investors who purchased the company's securities from March 7, 2024, to March 3, 2025. Key allegations include misleading statements made by the company regarding the effectiveness and safety of its PGN-EDO51 drug and issues with the CONNECT2 study, suggesting that PepGen's prospects may have been overstated. Investors are encouraged to contact the law firm for participation in the lawsuit.
Price reaction · baseline $1.45 (2025-06-11 close) · hit after-hours · 1 other PEPG headline(s) in the window, move may be shared
day 0 close
+1.4%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against PepGen, indicating potential legal trouble.
  • Allegations of materially false and misleading statements regarding the company's products.
  • Risks associated with the halted CONNECT2 study and the effectiveness of PGN-EDO51.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~22 mo
Low dilution risk
Lead asset
PGN-EDODM1
Phase 2 · Myotonic Dystrophy 1

Full Press Release Details

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against PepGen, Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) in the United States District Court for the Eastern District of New York on behalf of all persons and entities who purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”). Investors have until August 8, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
Click here to participate in the action.
The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) PGN-EDO51 was less effective and safe than Defendants had led investors to believe; (ii) the CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, Defendants' public statements were materially false and misleading at all relevant times.
If you purchased or otherwise acquired PepGen shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

What is the lawsuit against PepGen about?

The lawsuit claims PepGen made false statements about its business and the safety of PGN-EDO51.

Who can participate in the PepGen class action?

Anyone who purchased PepGen securities between March 7, 2024, and March 3, 2025, can participate.

When is the deadline to apply as lead plaintiff?

The deadline to apply as lead plaintiff is August 8, 2025.

How can I contact Bragar Eagel & Squire?

You can contact them via email at investigations@bespc.com or call (212) 355-4648.

What does Bragar Eagel & Squire specialize in?

The firm specializes in representing investors in complex litigation and securities issues.

Last updated: Jun 12, 2025